The specter of generic competition has repeatedly loomed over copyright’s famous drug, Viagra, raising questions about the future of related pharmaceutical investments. While first periods saw significant gains, the intellectual property lapse has opened the path for discounted alternatives, potentially reducing profitability and creating a genui